Long-term results of treatment of chronic hepatitis B, C and D with interferon- α in renal allograft recipients

Durlik, M.; Gaciong, Zbigniew; Rowińska, D; Rancewicz, Z; Lewandowska, Dorota; Kozłowska, B; Wyzgał, Janusz; Soluch, L; Walewska-Zielecka, Bożena; Rowińskí, W; M, Lao

doi:10.1007/s001470050445

Cited by 22 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our HCV infected renal transplant recipients did not have a higher mortality in contrast to several other studies (5, 7, 13, 22, 23). The better outcome of HCV positive patients in our centre might be explained by strict inclusion criteria for the transplant waiting list: HCV infected patients were only accepted for transplantation after histologic exclusion of active liver disease or cirrhosis.…”

Section: Discussioncontrasting

confidence: 87%

See 1 more Smart Citation

Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation

Breitenfeldt

Rasenack

Berthold

et al. 2002

Clinical Transplantation

101

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 87%

“…If HCV infection has occurred after transplantation, interferon therapy might be of value. However, interferon treatment after transplantation is associated with a high risk of irreversible acute allograft rejection (22). Therefore, we do not use it in our patients.…”

Section: Discussionmentioning

confidence: 99%

Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation

Breitenfeldt

Rasenack

Berthold

et al. 2002

Clinical Transplantation

101

View full text Add to dashboard Cite

show abstract

“…The most serious complication is acute parenchymatous or vascular transplant rejection or transplant necrosis 111 . Thus, INF therapy is not recommended in this patient group, except for those with chronic aggressive hepatitis 83,112,113 . Presently, a single study in the literature has reported on the positive treatment outcome of pegylated–INF‐α 2b in combination with ribavirin in HCV+ kidney transplant recipients.…”

Section: Hcv Infection Treatment In Dialysis Patientsmentioning

confidence: 99%

Hepatitis C virus infection in dialysis patients

Sułowicz

Radziszewski

Chowaniec

2007

Hemodialysis International

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a global health problem, common worldwide, leading to acute and chronic hepatitis and its consequences of hepatocirrhosis and hepatocellular carcinoma. Patients on hemodialysis belong to the high-risk group of HCV infection. The prevalence of HCV infection in dialysis patients ranges from 4% to more than 70% in some countries. The main reasons for such a high incidence of infections are a high prevalence of HCV infection in the general population, lack of standard infection precautions and effective vaccination, inadequate disinfection procedures of dialysis machines and other medical equipment, as well as spread of infection from patient to patient, especially in dialytic centers with a high percentage of infected patients. The diagnostic procedures useful in the evaluation of HCV infection are detection of anti-HCV antibodies, identification of HCV RNA, counts of virus copies, and identification of its genome. From the 6 major genotypes and multiple subtypes of the HCV, genotypes 1a and 1b are the most common in Europe and Japan, and 1b is responsible for more severe liver disease and aggressive course leading to liver fibrosis. Antiviral therapy of HCV+ dialysis patients with interferon-alpha (INF-alpha) gives slightly better results than in the general population, but is poorly tolerated and associated with side effects. Although ribavirin in not recommended for dialysis patients, the addition of small doses of this compound to pegylated INF is discussed, especially for patients in whom previous infection treatment failed.

show abstract

“…However, the use of this molecule remains controversial in KT recipients. One recent study suggests that IFN‐alpha can be used in renal transplant recipients [1], whereas several studies have highlighted an unacceptably high rate of allograft rejection because of the activation of immune responses induced by IFN‐alpha, which frequently leads to graft loss and requires chronic dialysis within weeks [2–10].…”

Section: Introductionmentioning

confidence: 99%

Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha

Hassan

Roche

Buffet

et al. 2012

Transplant International

View full text Add to dashboard Cite

Summary Antiviral therapy with interferon‐alpha (IFN‐alpha) and pegylated IFN‐alpha (PEG‐IFN‐alpha) for chronic hepatitis C (HCV)‐infected kidney recipients remains controversial. IFN‐alpha is not recommended in most cases because it induces severe acute graft rejection. However, IFN‐alpha, as PEG‐IFN‐alpha, is associated with a more pronounced immune response, and is well tolerated in HCV‐infected liver recipients without causing graft rejection. In combined liver–kidney transplant (LKT) recipients, IFN‐alpha has been occasionally used and appears to be well tolerated. All LKT recipients with a functioning kidney and liver having a HCV replication and who needed IFN‐alpha therapy have been included in the study. The occurrence of liver and/or renal acute rejection as well as the HCV replication has been collected. A total of 12 LKT patients treated with PEG‐IFN‐alpha plus ribavirin have been studied. No acute rejection was observed. Renal function remained stable during and after discontinuing treatment, without any graft dysfunction. Two patients had a partial viral response and four had a sustained viral response. All patients, whatever their viral response, had decreased liver‐enzyme levels. Response to PEG‐IFN‐alpha therapy was correlated with steroid dose and transaminase level when PEG‐IFN‐alpha was started. These data suggest that the combination therapy of PEG‐IFN‐alpha plus ribavirin did not have a higher risk of acute kidney‐graft rejection after liver–kidney transplantation.

show abstract

Long-term results of treatment of chronic hepatitis B, C and D with interferon- α in renal allograft recipients

Cited by 22 publications

References 12 publications

Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation

Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation

Hepatitis C virus infection in dialysis patients

Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha

Contact Info

Product

Resources

About